Artificial intelligence empowers full-stack histopathological diagnosis and prognosis of renal cell tumor: a multi-center study with external validation
- Journal
- BMC medicine (Q1)
- Published
- 4 August 2026
- Study design
- Prospective / inception cohort
- Evidence level
- Level 2, Moderate (CEBM 2b)
- Authors
- Ying Xiong, Wei Xi, Gelei Zhang, Xiaoyuan Luo, Li Xiao, Jianbo Gao, et al.
- PMID
- 42547870
- DOI
- 10.1186/s12916-026-05110-5
Why clinicians should know about it
- Picked for Pathology and Forensic Medicine (paper of the day, 5 August 2026).
- Picked for Health Informatics (paper of the day, 5 August 2026).
Abstract
BACKGROUND: The rapid advancement of digital pathology has opened unprecedented opportunities for intelligent diagnosis in renal cell tumor. However, there remains a significant gap in the availability of reliable deep learning models capable of comprehensive kidney cancer detection, classification, grading, and survival prediction. METHOD: This study retrospectively analyzed 11,135 whole-slide images (WSIs) from 7033 patients with renal tumor, sourced from four medical centers and two public cohorts. Histopathological representations were extracted using the foundation model Prov-GigaPath. A full-stack renal tumor diagnosis and prognosis framework was developed by combining fully supervised learning and weakly supervised multi-instance learning to enable both regional characterization and patient-level inference. RESULTS: The deep learning model demonstrated high accuracy in identifying normal tissue (AUC = 0.990), tumor tissue (AUC = 0.982), necrosis tissue (AUC = 0.994), sarcomatoid differentiation (AUC = 0.967), and pseudocapsule tissue (AUC = 0.990) across various pathological types of renal cell tumor. For nine major subtypes of renal cell tumor, classification AUC reached 0.956-0.998 across multi-center validation cohorts. WHO/ISUP nuclear grade prediction for clear cell renal cell carcinoma (ccRCC) and papillary renal cell carcinoma (pRCC) achieved an AUC of 0.867. A whole-slide-derived pan-renal cell tumor pathological risk score independently predicted overall survival and significantly outperformed WHO/ISUP grading in prognostic stratification (p < 0.001). CONCLUSIONS: We developed and validated a comprehensive AI framework integrating tissue-region detection, renal tumor subtype classification, nuclear grading, and survival prediction. These findings support its potential as a decision-support tool for renal tumor pathology, while prospective workflow-based studies are warranted to determine its clinical utility and impact on pathologist performance.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.